Biogen's Rare Disease Drugs Drive Quarter Beat, but Legacy MS Sales Lag
724FinanceEge Kaan
Key Highlights
Biogen, ikinci çeyrek kar ve gelir raporlarını Wall Street beklentilerini aşarak açıkladı. **$2.74 milyar** gelir ve **$3.60** pay başına kar elde ede
Biogen reported second-quarter profit and revenue exceeding Wall Street expectations, with $2.74 billion in revenue and $3.60 per-share earnings. Global sales of its Alzheimer's drug Leqembi rose 15% year-over-year, while legacy MS drugs like Tecfidera saw a 13% decline. The company cut its 2026 forecast to $12-$13 per share due to $3.85 acquisition-related charges from its $5.6 billion Apellis buyout. Markets are watching whether new products and the expanding rare disease portfolio can sustain growth.
Related News & Analysis
View All →
Binance Employees Arrested in UAE: Regulatory Pressure Intensifies
Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Latest Market News
All News →
Castelion Secures $13 Billion Valuation to Accelerate Hypersonic Missile Production
KAMUYU AYDINLATMA PLATFORMU Sermaye Piyasası Kurulu Tedbir Kararı / BAYRK - Sermaye Piyasası Kurulu Tedbir Kararı
Binance Employees Arrested in UAE: Regulatory Pressure Intensifies
İran, ABD Yaptırımlarını 'Ekonomik Terörizm' Dedi: Küresel Finansal Tabloları Huzursuzlaştırıyor
[YYAPI] YEŞİL YAPI ENDÜSTRİSİ A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu